Isofol Medical: Post-ASCO update

Research Note

2019-06-05

22:27

The annual meeting of the annual meeting of the American Society of Clinical Oncology (ASCO) is now over. No major, practise-changing advances were seen in colorectal cancer (CRC), but we saw some interesting results in the early stage pipeline and will monitor the development going forward. Overall, we continue to view Isofol’s competitive landscape as favourable.

AN

Arvid Necander

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.